LOS ANGELES--(BUSINESS WIRE)--Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed in the United States District Court for the Central District of California against Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE: AMPE), for alleged violations of the federal securities laws. Investors who purchased or otherwise acquired shares between January 13, 2014 and August 21, 2014, inclusive (the “Class Period”), have until July 7, 2015 to serve as lead plaintiff in the class action.
If you are a shareholder who suffered a loss during the Class Period, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Ampio is a biopharmaceutical company that develops therapies to treat various inflammatory conditions. The complaint alleges that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) the clinical research organization conducting the STEP Study lacked independence; (2) the trial drug supply for the STEP Study was shipped to clinical sites at lower temperatures than permitted by the drug specifications; and (3) as a result, the Company's public statements were materially false and misleading. When the truth was revealed, the stock dropped causing damage to investors.
If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
